ERBB2 and breast carcinoma: Chemotherapy is an essential part of management of non-metastatic breast cancer and is typically recommended for patients with locally advanced disease (e.g., primary tumours ≥5 cm or lymph node involvement) or those at increased risk of distant failure (e.g., cT2 N0 HER2-positive or triple-negative disease) [1,2,3].